Inotrem is an advanced clinical stage biotechnology company specialized in immunotherapy. The company has developed a new concept of immunomodulation that targets TREM-1, to control unbalanced and dysregulated inflammatory responses.
Inotrem targets the TREM-1 pathway as a key factor in unbalanced inflammatory responses. The company focuses on the therapeutic and diagnostic tools derived from its knowledge of the biology of the TREM-1 pathway.
Inotrem has 2 late-stage clinical programs ongoing in acute inflammatory diseases such as septic shock and COVID-19 with its lead product nangibotide. Inotrem also targets chronic inflammatory diseases through a broad anti-TREM monoclonal antibody program.
Inotrem targets the TREM-1 pathway as a key factor in unbalanced inflammatory responses. The company focuses on the therapeutic and diagnostic tools derived from its knowledge of the biology of the TREM-1 pathway
Inotrem has 2 late-stage clinical programs ongoing in acute inflammatory diseases such as septic shock and COVID-19 with its lead product nangibotide. Inotrem also targets chronic inflammatory diseases through a broad anti-TREM monoclonal antibody program.
Paris (France), November 6th. 2023. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today it received the second milestone-based funding from the American Crohn’s & Colitis
Paris (France), November 6th. 2023. Inotrem, an advanced clinical stage biotech company specialized in immunotherapies for acute and chronic inflammatory syndromes, announced today it received the second milestone-based funding from the American Crohn’s & Colitis
INOTREM S.A | 54 rue de Ponthieu 75008 PARIS
Follow us LinkedIn
Inotrem 2023 – Legal notices
INOTREM S.A | 54 rue de Ponthieu 75008 PARIS – Follow us LinkedIn
Inotrem 2023 – Legal notices